Should SGLT2 Inhibitors Be Stopped in Shocky Patients?
Yes, SGLT2 inhibitors should be withheld during critical medical illness, hemodynamic instability, or shock due to increased risk of ketoacidosis and volume depletion, though they may be cautiously continued in stable patients with chronic heart failure who are euvolemic and receiving adequate nutrition.
Clinical Reasoning
The most authoritative guidance comes from the KDIGO 2022 guidelines, which explicitly state: "It is reasonable to withhold SGLT2i during times of prolonged fasting, surgery, or critical medical illness (when patients may be at greater risk for ketosis)" 1. This recommendation is echoed in the 2020 KDIGO guidelines 2 and the 2022 Mayo Clinic consensus 3.
Key Pathophysiologic Concerns in Shock
SGLT2 inhibitors pose specific risks in hemodynamically unstable patients:
Ketoacidosis Risk: Critical illness, reduced food intake, and physiological stress increase counterregulatory hormones that drive ketone production. SGLT2 inhibitors lower the insulin/glucagon ratio, predisposing to euglycemic diabetic ketoacidosis (DKA) even with normal glucose levels (<200 mg/dL) 3, 4. Patients on insulin are at particularly high risk 4.
Volume Depletion: SGLT2 inhibitors have diuretic effects that can worsen hypovolemia in shock states. The 2022 Mayo Clinic guidelines note concerns about "volume depletion and hypovolemia due to their diuretic action" 3, though recent data suggest this may require slightly greater vasopressor support rather than causing frank hemodynamic collapse 5.
Metabolic Vulnerability: In malnourished or cachectic patients with advanced disease, SGLT2 inhibitors can precipitate life-threatening hypoglycemia and metabolic decompensation 6.
Practical Management Algorithm
When to STOP SGLT2 Inhibitors:
- Any form of shock (cardiogenic, septic, hypovolemic, distributive)
- Hemodynamic instability requiring vasopressors or inotropes
- Prolonged fasting or inability to maintain oral intake
- Active ketosis (ketones >1.0 mmol/L) or any signs of DKA
- Severe malnutrition (BMI <18.5 kg/m²) with advanced heart failure
- Emergency surgery or unplanned procedures
When CONTINUATION May Be Considered:
Recent evidence suggests SGLT2 inhibitors may be cautiously continued in specific circumstances 5, 7:
- Patient is hemodynamically stable (not requiring vasopressors)
- Euvolemic status confirmed
- Receiving adequate nutrition (oral or enteral)
- Heart failure indication where abrupt discontinuation may worsen cardiovascular status 7
- Close monitoring available for ketones and glucose
Timing of Discontinuation
For elective procedures, the 2025 UK multidisciplinary consensus recommends stopping SGLT2 inhibitors at least 24-48 hours pre-operatively (minimum 36 hours if evening dosing, 48-52 hours if morning dosing) 8. For emergency situations or shock, discontinue immediately.
Critical Monitoring Requirements
If SGLT2 inhibitors are continued in borderline-stable patients:
- Blood ketone monitoring (not just glucose) - target <1.0 mmol/L 1, 8
- Volume status assessment - watch for orthostatic changes
- Vasopressor requirements - may increase modestly 5
- Nutritional intake - ensure adequate carbohydrate provision
- Daily reassessment of appropriateness of continuation
Common Pitfalls to Avoid
Assuming normal glucose excludes DKA: Euglycemic DKA can occur with glucose <200 mg/dL 3, 4. Always check ketones in critically ill patients on SGLT2 inhibitors.
Overlooking non-diabetic patients: Even patients without diabetes can develop euglycemic ketoacidosis on SGLT2 inhibitors during critical illness 8.
Continuing during prolonged NPO status: Fasting states dramatically increase ketoacidosis risk. Withhold the drug and consider glucose-containing IV fluids 8.
Inadequate ketone monitoring: Only 34.6% of ICUs have documented ketone measurement policies, and practice varies widely 9. Establish systematic monitoring protocols.
Abrupt discontinuation in stable heart failure: In hemodynamically stable patients with heart failure as the primary indication, abrupt cessation may worsen cardiovascular outcomes 7. This requires nuanced decision-making.
Evidence Quality Considerations
The guideline recommendations are based on Practice Points rather than formal graded recommendations, reflecting limited direct evidence in critically ill populations 2, 1. Recent observational data from ICU settings show that 51.9% of patients had SGLT2 inhibitors discontinued, primarily due to EDKA concerns, but practice varies widely 9. Emerging research suggests safety in selected stable ICU patients 5, but the absence of harm in observational studies does not override the physiologic rationale for caution in shock states.
The safest approach in shock or hemodynamic instability is discontinuation, with consideration for continuation only in truly stable patients where heart failure benefits clearly outweigh ketoacidosis risks 1, 8, 7.